2月4日，Turnstone生物制药公司因制造成本过高，终止了其最后一个临床阶段的肿瘤浸润淋巴细胞（TIL）疗法项目 TIDAL-01 ，并计划进一步裁员。此举紧随该公司去年十月裁员60%之后，旨在最大限度地提高股东价值。TIDAL-01 ...

▎药明康德内容团队编辑艾伯维（AbbVie）公司今日宣布，美国FDA已批准该公司与辉瑞（Pfizer）联合开发的Emblaveo（aztreonam和avibactam）上市，与甲硝唑联合使用，治疗18岁及以上复杂性腹腔内感染（cIAI）患者，包括由 ...

Emblaveo marks the first and only fixed-dose intravenous monobactam/β-lactamase inhibitor combination antibiotic to be ...

智通财经APP获悉，艾伯维(ABBV.US)公司宣布，美国FDA已批准该公司与辉瑞(PFE.US)联合开发的Emblaveo(aztreonam和avibactam)上市，与甲硝唑联合使用，治疗18岁及以上复杂性腹腔内感染(cIAI)患者，包括由多种 ...

AbbVie announced that the US FDA has approved aztreonam and avibactam (Emblaveo), in combination with metronidazole, for ...

AbbVie has received US Food and Drug Administration (FDA) approval for Emblaveo (aztreonam and avibactam) to be used in ...

EMBLAVEO与甲硝唑联合使用，针对特定革兰氏阴性细菌引起的感染，包括大肠杆菌和肺炎克雷伯菌等。该批准基于该药物有限的临床安全性和有效性数据，解决了抗菌素耐药性（AMR）防控的关键需求。如果不加以解决，AMR可能在2050年前导致全球超过3,900万人死亡。凭借70.4%的强劲毛利率和稳健的现金流，AbbVie有能力支持这一重要治疗方案的商业化。投资者可通过 InvestingPro ...

AbbVie has announced that the US Food and Drug Administration (FDA) has approved its Pfizer-partnered Emblaveo ...

The FDA has approved Emblaveo with metronidazole for patients with complicated intra-abdominal infections and limited options.

Aztreonam–avibactam is a promising treatment for complicated intra-abdominal infections and hospital-acquired or ...

The intravenous antibiotic Emblaveo, a combination of aztreonam and avibactam approved in Europe last year, was developed in ...

AbbVie has announced that the U.S. Food and Drug Administration (FDA) has approved EMBLAVEO (aztreonam and avibactam), as a ...